YS Biopharma Co., Ltd. (YS)
NASDAQ: YS · IEX Real-Time Price · USD
1.51
+0.01 (0.67%)
May 31, 2023, 4:00 PM EDT - Market closed
Income Statement (Annual)
Financials in millions CNY. Fiscal year is April - March.
Millions CNY. Fiscal year is Apr - Mar.
| Year | 2021 | 2020 |
|---|---|---|
| Revenue | 502.95 | 257.02 |
| Revenue Growth (YoY) | 95.69% | - |
| Cost of Revenue | 117.07 | 59.66 |
| Gross Profit | 385.88 | 197.36 |
| Selling, General & Admin | 293.62 | 228.82 |
| Research & Development | 211.22 | 94.39 |
| Operating Expenses | 504.84 | 323.21 |
| Operating Income | -118.96 | -125.85 |
| Interest Expense / Income | 2.72 | 29.69 |
| Other Expense / Income | -20.61 | 18.83 |
| Pretax Income | -101.07 | -174.37 |
| Income Tax | 4.94 | 17.45 |
| Net Income | -106 | -191.83 |
| Preferred Dividends | 130.66 | 16.61 |
| Net Income Common | -236.67 | -208.44 |
| Shares Outstanding (Basic) | 247 | 247 |
| Shares Outstanding (Diluted) | 247 | 247 |
| EPS (Basic) | -0.43 | -0.78 |
| EPS (Diluted) | -0.43 | -0.78 |
| Free Cash Flow Per Share | -1.90 | -1.42 |
| Gross Margin | 76.72% | 76.79% |
| Operating Margin | -23.65% | -48.96% |
| Profit Margin | -47.06% | -81.10% |
| Free Cash Flow Margin | -93.22% | -136.51% |
| EBITDA | -63.41 | -114.54 |
| EBITDA Margin | -12.61% | -44.57% |
| Depreciation & Amortization | 34.94 | 30.14 |
| EBIT | -98.35 | -144.68 |
| EBIT Margin | -19.55% | -56.29% |
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).